Conexeu Sciences (NASDAQ:CNXU) Releases Earnings Results, Misses Estimates By $0.19 EPS

Conexeu Sciences (NASDAQ:CNXU) announced its earnings results on Monday. The company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.19), Zacks reports.

Conexeu Sciences Trading Up 12.1%

Shares of Conexeu Sciences stock traded up $0.54 on Monday, hitting $5.00. The stock had a trading volume of 189,629 shares, compared to its average volume of 157,771. The firm has a market capitalization of $133.80 million and a PE ratio of -45.45. Conexeu Sciences has a twelve month low of $4.19 and a twelve month high of $18.79. The company has a 50 day moving average price of $8.09.

Insider Activity

In other Conexeu Sciences news, Director Lynn Sebastian Purcell acquired 202,500 shares of the company’s stock in a transaction on Thursday, June 18th. The stock was acquired at an average price of $0.80 per share, for a total transaction of $162,000.00. Following the purchase, the director directly owned 2,734,240 shares of the company’s stock, valued at $2,187,392. This trade represents a 8.00% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Analysts Set New Price Targets

CNXU has been the topic of several recent research reports. Zacks Research upgraded shares of Conexeu Sciences to a “hold” rating in a research note on Monday, June 29th. Weiss Ratings began coverage on Conexeu Sciences in a research report on Monday, August 17th. They issued a “sell (e-)” rating on the stock. HC Wainwright started coverage on Conexeu Sciences in a research report on Monday, June 22nd. They set a “buy” rating and a $20.00 price target for the company. Finally, Wall Street Zen raised Conexeu Sciences to a “hold” rating in a research report on Saturday, May 30th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Conexeu Sciences has a consensus rating of “Hold” and an average price target of $20.00.

About Conexeu Sciences

Conexeu is a company focused on building a new class of collagen-based regenerative tissue products. The Company was incorporated on November 2, 2022 under the Business Corporations Act (British Columbia) and was continued out of British Columbia and domesticated into the State of Nevada under the laws of the State of Nevada on April 10, 2025. — Conexeu is an early-stage medical device company formed to acquire and commercialize intellectual property (“IP”) developed over more than a decade at the University of British Columbia (the “University”) and the BC Professional Firefighters Burn and Wound Healing Laboratory.